Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?

CMAJ. Canadian Medical Association Journal

Volumn 174, Issue 8, 2006, Pages 1090-1091

  Hiralal, Rajesh ^a   Koo, Karen K Y ^a   Gerstein, Hertzel C ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; PIOGLITAZONE; ANTIDIABETIC AGENT; PLACEBO;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG TOLERANCE; DYSLIPIDEMIA; EDEMA; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; LEG ULCER; LIVER DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RISK REDUCTION; SHORT SURVEY; STROKE; ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PLACEBOS; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 33645949716     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060049     Document Type: Short Survey

References (3)

1. Herz M, Johns D, Reviriego J, et al; the GLAB study group. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 2003;25:1074-95.
2. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003;26:2983-9.
3. Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005;22:986-93.